Kuickresearch::Industry News

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |

Novel Gene Therapy Market to Introduce Microneedle Market for Boosting the Treatment Effectiveness

Release Date: 16 November 2020

The novel gene therapy market is witnessed to be having great potential in the treatment of different diseases such as cancer, genetic defects and different immunological diseases. The main mechanism of action of the gene therapy is by d...

Read More


Dendritic Cell Vaccine Causing the Strengthening of Immune System in Alzheimer’s Disease

Release Date: 16 November 2020

Immune system acts as a major defense system in case a foreign particle attacks a human body. It has been observed that immunotherapy that targets peptide amyloid beta which is one of the most important protein involved in Alzheimer&rsqu...

Read More


Small Molecule and Protein Interaction to Become Novel Therapeutic Target for Alzheimer’s Disease

Release Date: 16 November 2020

A novel research study indicates that drugs that can target star shaped shifting protein in case of Alzheimer’s disease can be designed, which years ago was thought to be impossible by the researchers. A group of researchers from t...

Read More


PEG Layered Nanoparticles to Cross Blood Brain Barrier for Efficient Delivery of the Parkinson’ Disease Drugs

Release Date: 16 November 2020

In the global therapeutic world, it is clear that nanoparticles are among the most important transport agents, as it can deliver drugs more promisingly to the brain, opening neurological disorders such as Parkinson’s disease. It is...

Read More


Covid-19 Impact on CAR-T Cell Therapy Clinical Trial for the Patients Suffering from DLBCL

Release Date: 16 November 2020

Covid-19 is the ongoing pandemic at global level with no cure, therefore, researchers across the globe are now focused towards developing an efficient treatment for the disease. Researchers from Levine Cancer Institute are oriented towar...

Read More


Infused Vesicles to get Recognized as Novel Therapeutic Treatment for Multiple Sclerosis 02-Dec

Release Date: 16 November 2020

All the available therapies for multiple sclerosis are estimated to modulate the immune system so that the impact of multiple sclerosis on protective myelin sheaths around nerve cells could be protected, which is also one of the most imp...

Read More


Netrin-G Blocking to Effectively Emerge as Novel Pancreatic Cancer Treatment

Release Date: 15 November 2020

A group of researchers have discovered a novel protein that is estimated to be playing pivotal role in the development of the neurons in the brain as well as the development and growth of the pancreatic cancer cells. The protein discover...

Read More


Immunotherapy Effective Results with respect to Cervical Cancer Pseudoprogression Events

Release Date: 15 November 2020

Immune checkpoint inhibitors effectiveness was observed in the patients suffering from recurrent cervical cancer, including early, delayed, and serial events. The primary aim of the research conducted with respect to the testing of immun...

Read More


AMG-509 Targeting Prostate Cancer Patients Expressing STEAP1 Protein

Release Date: 15 November 2020

Immunotherapy has always remained as a novel therapeutic for number of complex diseases specifically cancer. Now-a-days, a novel immunotherapy drug called as AMG 509 is getting evaluated for its activity in treating prostate cancer cells...

Read More


Cancer Treatment to get a Novel Immunotherapy Drug Candidate

Release Date: 15 November 2020

Researchers have identified a novel drug that is capable of generating an immune response in the body against the cancer cells. The primary aim of the developed drug by the researchers from Cancer Research UK is suppressive ‘regula...

Read More


Novel Monoclonal Antibody Therapy Meeting the Needs of Non-Small Cell Lung Cancer Patients

Release Date: 15 November 2020

Researchers have bene trying to evaluate the primary end point of overall survival (OS) with tislelizumab compared with docetaxel as an effective treatment of patients with locally advanced or metastatic non–small cell lung cancer ...

Read More


Monoclonal Antibodies to Emerge as a Novel Treatment against Covid-19 Soon

Release Date: 14 November 2020

Covid-19 is an emerging pandemic at global level, therefore hundreds of bio-pharmaceutical companies at the current time are focusing towards conducting clinical researches including different therapies for the eradication of the virus f...

Read More


Ibalizumab Boosting the Body’s Immune Response against HIV

Release Date: 14 November 2020

HIV is an emerging disease in the whole world therefore, thousands of researchers are currently inclined towards finding a permanent cure for the disease. On the other side, Ibalizumab is estimated to be an efficient drug that could prev...

Read More


TJ210/MOR210 Successful Clinical Research Outcomes in Immunology Market

Release Date: 14 November 2020

The pre-clinical data of an antibody developed by I-Mab against cancer is estimated to be important for inhibition of the tumor cells attacking immune cell as well as promotion of tumor progression. The project under which the study is g...

Read More


Novel Monoclonal Antibody Efficiency in Treating Multiple Myeloma

Release Date: 14 November 2020

A group of researchers are focusing the treatment of multiple myeloma as the cancer type has been one of the most prominent reasons for majority of cancer deaths. For the treatment of multiple myeloma, a novel therapeutic monoclonal anti...

Read More


1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |

Need custom market research solution? We can help you with that too.